ログイン
ランキング
お知らせ
ログイン
文献詳細
文献概要
特集 肺高血圧症Cutting Edge Ⅱ．肺高血圧症：何が原因か，なぜ原因となるのか？
慢性肺血栓塞栓症および肺高血圧への進展メカニズム
著者： 荻原義人1 山田典一2
所属機関： 1三重大学医学部附属病院循環器内科 2桑名市総合医療センター循環器内科
ページ範囲：P.354 - P.360
文献購入ページに移動Point
・急性の肺血栓塞栓は，癌，脾摘，血液型，感染，炎症，凝固・線溶系異常，血小板機能異常，血管新生障害などにより，溶けきらず残存し，線維性増殖因子や筋線維芽細胞などの働きにより，線維性の器質化血栓となる．
・慢性血栓塞栓性肺高血圧症（CTEPH）の成立には器質化血栓による狭窄・閉塞だけではなく，末梢血管病変の関与も重要である．
・急性の肺血栓塞栓は，癌，脾摘，血液型，感染，炎症，凝固・線溶系異常，血小板機能異常，血管新生障害などにより，溶けきらず残存し，線維性増殖因子や筋線維芽細胞などの働きにより，線維性の器質化血栓となる．
・慢性血栓塞栓性肺高血圧症（CTEPH）の成立には器質化血栓による狭窄・閉塞だけではなく，末梢血管病変の関与も重要である．
参考文献
1) 循環器病の診断と治療に関するガイドライン（2011年度合同研究班報告）：肺高血圧症治療ガイドライン（2012年改訂版）．2012
2) Simonneau G, Torbicki A, Dorfmuller P, et al:The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 26, 2017
3) Pepke-Zaba J, Jansa P, Kim NH, et al:Chronic thromboembolic pulmonary hypertension:role of medical therapy. Eur Respir J 41:985-990, 2013
4) Nakamura M, Miyata T, Ozeki Y, et al:Current venous thromboembolism management and outcomes in Japan. Circ J 78:708-717, 2014
5) Donnellan E, Kevane B, Bird BR, et al:Cancer and venous thromboembolic disease:from molecular mechanisms to clinical management. Curr Oncol 21:134-143, 2014
6) Bonderman D, Jakowitsch J, Adlbrecht C, et al:Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93:512-516, 2005
7) Sharma S, Lang IM:Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. Thromb Res, 2017［Epub ahead of print］
8) Bonderman D, Turecek PL, Jakowitsch J, et al:High prevalence of elevated clotting factor Ⅷ in chronic thromboembolic pulmonary hypertension. Thromb Haemost 90:372-376, 2003
9) Bonderman D, Wilkens H, Wakounig S, et al:Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 33:325-331, 2009
10) Wolf M, Boyer-Neumann C, Parent F, et al:Thrombotic risk factors in pulmonary hypertension. Eur Respir J 15:395-399, 2000
11) Kyrle PA, Minar E, Hirschl M, et al:High plasma levels of factor Ⅷ and the risk of recurrent venous thromboembolism. N Engl J Med 343:457-462, 2000
12) Suntharalingam J, Goldsmith K, van Marion V, et al:Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 31:736-741, 2008
13) Morris TA, Marsh JJ, Chiles PG, et al:Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173:1270-1275, 2006
14) Yaoita N, Satoh K, Satoh T, et al:Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension. Arterioscler Thromb Vasc Biol 36:1293-1301, 2016
15) Yaoita N, Shirakawa R, Fukumoto Y, et al:Platelets Are Highly Activated in Patients of Chronic Thromboembolic Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology 34:2486-2494, 2014
16) Zabini D, Nagaraj C, Stacher E, et al:Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS One 7:e43793, 2012
17) Alias S, Redwan B, Panzenboeck A, et al:Defective angiogenesis delays thrombus resolution:a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 34:810-819, 2014
18) Quarck R, Wynants M, Verbeken E, et al:Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J 46:431-443, 2015
19) Zabini D, Heinemann A, Foris V, et al:Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J 44:951-962, 2014
20) Langer F, Schramm R, Bauer M, et al:Cytokine response to pulmonary thromboendarterectomy. Chest 126:135-141, 2004
21) Maruoka M, Sakao S, Kantake M, et al:Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension. Int J Cardiol 159:119-127, 2012
22) Piera-Velazquez S, Li Z, Jimenez SA:Role of endothelial-mesenchymal transition（EndoMT）in the pathogenesis of fibrotic disorders. Am J Pathol 179:1074-1080, 2011
23) Mori L, Bellini A, Stacey MA, et al:Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 304:81-90, 2005
24) Phan SH:The myofibroblast in pulmonary fibrosis. Chest 122:286s-289s, 2002
25) Ro A, Kageyama N, Tanifuji T, et al:Autopsy-proven untreated previous pulmonary thromboembolism:frequency and distribution in the pulmonary artery and correlation with patients' clinical characteristics. J Thromb Haemost 9:922-927, 2011
26) Moser KM, Bloor CM:Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103:685-692, 1993
27) 日本肺高血圧・肺循環学会：慢性肺血栓塞栓性肺高血圧症（CTEPH）診療ガイドライン．2018
28) Tanabe N, Sugiura T, Tatsumi K:Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension. Respir Investig 51:134-146, 2013
29) Tanabe N:Diagnosis and vasculopathy in chronic thromboembolic pulmonary hypertension. Ann Vasc Dis 2:136-143, 2009
30) Heath D, Edwards JE:The pathology of hypertensive pulmonary vascular disease;a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18:533-547, 1958
31) Ro A, Kageyama N, Ando M, et al:An Autopsy Case of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Thromboendarterectomy:Histopathological Character of Pulmonary Artery. The Japanese Journal of Phlebology 27:21-26, 2016
32) Dorfmuller P, Gunther S, Ghigna MR, et al:Microvascular disease in chronic thromboembolic pulmonary hypertension:a role for pulmonary veins and systemic vasculature. Eur Respir J 44:1275-1288, 2014
掲載誌情報
